Pharming GroupPHAR
About: Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
Employees: 382
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
39% more capital invested
Capital invested by funds: $369K [Q3] → $514K (+$145K) [Q4]
20% more funds holding
Funds holding: 5 [Q3] → 6 (+1) [Q4]
0% more ownership
Funds ownership: 0.01% [Q3] → 0.01% (+0%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis 19% 1-year accuracy 78 / 419 met price target | 345%upside $37 | Buy Reiterated | 21 Mar 2025 |
Oppenheimer Michael Carrier 50% 1-year accuracy 5 / 10 met price target | 369%upside $39 | Outperform Maintained | 14 Mar 2025 |
Financial journalist opinion
Based on 4 articles about PHAR published over the past 30 days









